Menu Back to DIA-FDA-Oligonucleotide-based-Therapeutics-Conference

Program Committee

  • Jim  Zisek
    Jim Zisek Director, Global CMC Regulatory Affairs GlaxoSmithKline, United States
  • Robert T. Dorsam, PhD
    Robert T. Dorsam, PhD Pharmacology/Toxicology Team Leader, Office of Generic Drugs, CDER FDA, United States
  • Daniel  Capaldi, PhD
    Daniel Capaldi, PhD Vice President, Analytical and Process Development Isis Pharmaceuticals, Inc., United States
  • Arthur A. Levin, PhD
    Arthur A. Levin, PhD Executive Vice President, Research and Development Avidity NanoMedicines, United States
  • Jan Kevin Losos, PhD
    Jan Kevin Losos, PhD Director, Safety Assessment Projects GlaxoSmithKline, United States
  • Saraswathy  V. Nochur, PhD, MSc
    Saraswathy V. Nochur, PhD, MSc Senior Vice President, Regulatory Affairs & QA Alnylam Pharmaceuticals, Inc., United States
  • Ramesh  Raghavachari, PhD
    Ramesh Raghavachari, PhD Chief, Branch I - DPMA1/OLDP/OPQ/CDER FDA, United States
  • David H. Schubert
    David H. Schubert Vice President of Regulatory & Quality Stealth BioTherapeutics, United States
  • Pengfei  Song, PhD
    Pengfei Song, PhD Senior Clinical Phamacology Reviewer in Oncology, CDER FDA, United States
  • James  Wild, PhD
    James Wild, PhD Pharmacologist, CDER FDA, United States
  • Rosanne  Seguin, PhD
    Rosanne Seguin, PhD McGill University, Canada
  • Scott  Henry, PhD
    Scott Henry, PhD Vice President, Nonclinical Development Isis Pharmaceuticals Inc., United States
Load More